At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
dutasteridedrug
Likely dose
dutasteride 3.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of MRI and Spectroscopy Imaging Changes With 6-months of Dutasteride in Patients With Symptomatic Benign Prostatic Hypertrophy and Low-risk Prostate Cancer on Watchful Waiting or Requiring Neoadjuvant Androgen Suppression Prior to Prostate Brachytherapy
In Brief
A clinical study evaluating dutasteride for Nonmalignant Neoplasm and Prostate Cancer. Completed, enrolled 10 participants across 1 site.
Detailed Summary
RATIONALE: Diagnostic procedures, such as MRI and magnetic resonance spectroscopy imaging, may help in learning how well dutasteride works in patients with benign prostatic hypertrophy and low-risk prostate cancer. PURPOSE: This clinical trial is studying MRI and magnetic resonance spectroscopy imaging in patients receiving dutasteride for benign prostatic hypertrophy and low-risk prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonmalignant Neoplasm, Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedJun 2008
Primary CompletionDec 2008
Study CompletionAug 2011
TodayJul 2026
First PostedJun 30, 2008
Enrollment StartJun 1, 2005
Primary CompletionDec 1, 2008
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.0 years ago
Interventions
dutasteridedrug
6 months of dutasteride 3.5 mg daily